Hum. Reprod. Advance Access published online on April 15, 2008
Human Reproduction, doi:10.1093/humrep/den102
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Success rates and cost of a live birth following fresh assisted reproduction treatment in women aged 45 years and older, Australia 2002–2004
1 Perinatal and Reproductive Epidemiology and Research Unit, School Women's and Children's Health, University of New South Wales, McNevin Dickson Building, Randwick Hospitals Campus, Randwick, NSW 2031, Australia 2 Discipline of Obstetrics and Gynaecology, School Women's and Children's Health, University of New South Wales, Royal Hospital for Women, Locked Bag 2000, Randwick, NSW 2031, Australia
3 Correspondence address. Tel: +61-2-9382-1014; Fax: +61-2-9382-1025; E-mail: e.sullivan{at}unsw.edu.au
BACKGROUND: The aim of this study was to calculate assisted reproductive technology (ART) success rates for fresh autologous and donor cycles in women aged
45 and the resultant cost per live birth.
METHODS: We performed a retrospective population-based study of 2339 ART cycles conducted in Australia, 2002–2004 to women aged
45 years. The cost-outcome study was performed on fresh autologous treatment cycles.
RESULTS: There were 1101 fresh autologous cycles initiated in women aged
45, with a pregnancy rate of 1.9 per 100 initiated cycles. There were 21 women who achieved a clinical pregnancy with 15 (71%) ending in early pregnancy loss and 6 in live singleton births. The live birth rate following fresh autologous initiated cycles was 0.5% [95% confidence interval (CI): 0.1–1.0%]. Fresh donor recipients had an higher live birth rate of 19.1% (95% CI: 15.1–23.2) (odds ratio 43.2; 95% CI: 18.6–100.3) compared with women having fresh autologous cycles. The average cost of a live birth following fresh autologous cycles was
753 107.
CONCLUSIONS: The success rate of fresh autologous treatment for women aged
45 years was <1%. The very high cost of a live birth reflects a treatment failure rate of >99%. The ART profession should counsel patients of the reality of the technology before the patients consent to treatment.
Key words: donor cycle/maternal age/cost/autologous cycle/assisted reproductive technology
Submitted on October 31, 2007; resubmitted on February 13, 2008; accepted on February 26, 2008.